GE HealthCare Technologies Inc.Opportunity Rank #248(GEHC) Intrinsic Value & DCF Analysis (2026)
Current Price
$61.34
Last updated: May 08, 2026
Price vs Intrinsic Value
Fundamental Score
Weighted across 6 signals
Narrative Score
+1 vs previous
Trend Score
As of 2026-05-08
The intrinsic value of GE HealthCare Technologies Inc. (GEHC) is estimated at $67.45 per share based on a 10-year discounted cash flow (DCF) analysis. At the current price of $61.34, the stock appears undervalued relative to its projected cash flow fundamentals. This estimate assumes a 2.77% long-term growth rate and a 9.00% discount rate (calculated: 7.41%), reflecting expected future free cash flow and cost of capital.
The intrinsic value of GE HealthCare Technologies Inc. (GEHC) is estimated at $67.45 per share based on a 10-year discounted cash flow (DCF) analysis. At the current price of $61.34, the stock appears undervalued relative to its projected cash flow fundamentals. This estimate assumes a 2.77% long-term growth rate and a 9.00% discount rate (calculated: 7.41%), reflecting expected future free cash flow and cost of capital.Valuation Details
Capital Efficiency
The company is earning below its required return. This may indicate inefficient use of capital or excess cash that isn't being reinvested.
Fundamental Details
Narrative Details
Trend Details
Investment Coach
- Monitor whether valuation discount remains above 10%.
- Track ROIC versus WACC spread for sustained improvement.
- Follow narrative trend for meaningful shifts in the score direction.
Free Cash Flow (in millions)
How Intrinziq Estimates Fair Value
Intrinziq estimates GE HealthCare Technologies Inc.'s intrinsic value using a discounted cash flow (DCF) model based on free cash flow trends and a market-based discount rate. The model projects future cash flows over ten years and discounts them using a market return assumption to estimate fair value.
GE HealthCare Technologies Inc.Healthcare
GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, Europe, the Middle East, Africa, China, Taiwan, Mongolia, Hong Kong, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, image-guided therapy, and X-ray systems, as well as women's health products. The Ultrasound segment provides screening, diagnosis, treatment, and monitoring of certain diseases through radiology and primary care, women's health, cardiovascular, and point of care and handheld ultrasound solutions, as well as surgical visualization and guidance products. The Patient Care Solutions segment involved in the provision of medical devices, consumable products, services, and digital solutions through patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, and maternal infant care products. The Pharmaceutical Diagnostics supplies diagnostic agents, including CT, angiography and X-ray, MR, single-photon emission computed tomography, positron emission tomography, and ultrasound to the radiology and nuclear medicine industry. The segment also provides contrast media pharmaceuticals, administered to a patient prior to certain diagnostic scans to increase the visibility of tissues or structures during imaging exams; and molecular imaging agents, or radiopharmaceuticals, which are molecular tracers labeled with radioisotopes that are injected into a patient prior to a diagnostic imaging scan. The company was incorporated in 2022 and is headquartered in Chicago, Illinois.